RESULTS and METHODS
The Registry was initially created in 1993; since then, enrollment has been prospective. Full description of Registry methods is available elsewhere.2 The common definition of SDS was applied,10 and all patients reported carried a molecularly confirmed SBDS mutation. The cutoff date was 31 May 2020. Cancers were classified according to the World Health Organization classification during a centralized review of the tumor samples (JFE) subjected to NGS analysis somatic study. Among the 155 patients included in this study [median follow-up: 16.4 years (2742 person-years)], three developed solid tumors during their monitoring. The cancer rate was 0% by the age of 40 years but increased dramatically during the 5th decade (Figure 1). Their clinical histories are described. They were all followed according to published guidelines10 and none have presented, prior cancer diagnosis a myelodysplasia, and none have received GCSF prior cancer diagnosis.